TNB-486 在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的研究
TNB-486 的多中心、1 期、开放标签、剂量递增和扩展研究，TNB-486 是一种针对复发或难治性 B 细胞非霍奇金淋巴瘤受试者的双特异性抗体
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
研究概览
详细说明
This dose escalation and optimization study, is evaluating the safety, tolerability, PK, PD and clinical activity of AZD0486 monotherapy.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Kaohsiung City、台湾、833401
- Research Site
-
Kweishan、台湾、333
- Research Site
-
Tainan、台湾、704
- Research Site
-
Taipei、台湾、10002
- Research Site
-
-
-
-
-
Chūōku、日本、104-0045
- Research Site
-
Kōtoku、日本、135-8550
- Research Site
-
Nagoya、日本、460-0001
- Research Site
-
Yamagata、日本、990-9585
- Research Site
-
-
-
-
-
Heidelberg、澳大利亚、3084
- Research Site
-
Hobart、澳大利亚、7000
- Research Site
-
Melbourne、澳大利亚、3004
- Research Site
-
-
-
-
Florida
-
Tampa、Florida、美国、33612
- Research Site
-
-
Kentucky
-
Louisville、Kentucky、美国、40207
- Research Site
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08901
- Research Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Research Site
-
-
Ohio
-
Columbus、Ohio、美国、43210
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15237
- Research Site
-
-
Texas
-
Austin、Texas、美国、78704
- Research Site
-
Houston、Texas、美国、77030
- Research Site
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Research Site
-
-
-
-
-
Seoul、韩国、03080
- Research Site
-
Seoul、韩国、05505
- Research Site
-
Seoul、韩国、06351
- Research Site
-
Seoul、韩国、06591
- Research Site
-
Seoul、韩国、120-752
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Biopsy proven B-NHL, including DLBCL, HGBL, or FL.
- Relapsed/refractory cohorts:
In order to be eligible subjects must have received at least 2 prior lines of therapy and not be candidates for treatment regimens known to provide clinical benefit in B-NHL. CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies.
- 1L FL cohorts: Subject has biopsy-proven FL Grade 1-3a per WHO 2016 classification, Stage II-IV, FL International Prognostic Index 2-5 that has not been treated with prior systemic lymphoma-directed therapy and requires initiation of treatment based on GELF criteria. Radiation to localized disease prior to study entry is allowed if >14 days from first dose.
- All Cohorts:
Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
- Subject must have adequate liver, bone marrow and kidney function (eGFR ≥ 50 mL/min).
- Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received)
- Subject must have at least 1 measurable disease site
- Subject must have ANC >/= 1000/mm3, platelets >/= 50,000 mm3, hemoglobin >/= 8.0 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening
- Subject must have a total bilirubin <1.5x ULN, AST/ALT < 3xULN
Exclusion Criteria:
- Subject has been diagnosed with or treated for another malignancy whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen.
- Subject has active central nervous system (CNS) involvement by their B-NHL. --Subjects may be eligible with a distant history of CNS involvement that has been adequately treated with no evidence of recurrence within last 6 months from screening.
- Subject has a history of leukemic presentation of their B-NHL (>5,000 circulating lymphoma cells/uL in the peripheral blood).
- Subject has history or presence of clinically significant CNS pathology
- Subject has CNS involvement from active or history of autoimmune disease.
- Subject received CD19 CAR T therapy within 3 months prior to first dose.
- Subject experienced Grade ≥ 3 cytokine release syndrome (CRS) following prior T-cell engager (TCE) or CAR T-cell therapy.
- Subject experienced Grade ≥ 2 neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) following prior TCE or CAR T-cell therapy.
- Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study drug treatment or has received an SCT and requires ongoing immunosuppressive therapy.
- Subjects with human immunodeficiency virus (HIV) infection, or subjects with chronic or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Subjects with chronic HBV may be enrolled if the HBV viral load is undetectable on suppressive therapy, or if the subject has a documented cure. Subjects with HCV who have a documented cure may be enrolled.
- Subject has a history of major cardiac abnormalities.
- If female, subject must not be pregnant or breastfeeding.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：顺序分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：AZD0486 Monotherapy Dose Escalation in Subjects with B-NHL
AZD0486 monotherapy will be administered intravenously on day 1 and 15 of 28 day cycles for a maximum of 2 years or until discontinuation criteria are met. Depending on cohort, subjects may receive priming or step-up dosing administered weekly during cycle 1 before reaching the target dose. Additional cohorts may be opened where subjects receive weekly dosing during Cycles 1-2. While on study, subjects will be monitored for safety and efficacy with periodic disease assessment with PET/CT. If subject achieves two consecutive CRs after completing C6, then they may be eligible for monthly dosing |
AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of subjects with Dose-limiting toxicities (DLT)
大体时间：28 days
|
A DLT is defined as a TEAE that is not unequivocally due to the subject's underlying malignancy or other extraneous cause. DLT evaluable subjects are defined as those subjects who receive either the target dose of AZD0486 or priming dose(s) in any step-up dose schedule and are assessed for toxicities for the 28-day evaluation period. The NCI-CTCAE version 5.0 will be used (except for CRS and NT). A DLT will be evaluated as Non-hematologic, Hematologic, Cytokine Release Syndrome (CRS), or neurotoxicity. |
28 days
|
|
Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs)
大体时间：From screening until 90 Days after end of treatment
|
The incidence, timing, seriousness, and relationship to study treatment of adverse events will be evaluated. |
From screening until 90 Days after end of treatment
|
|
Maximum Observed Serum Concentration of AZD0486 (Cmax)
大体时间：4 Weeks
|
The maximum observed serum concentration on a concentration time curve. |
4 Weeks
|
|
Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast)
大体时间：4 Weeks
|
Area under the serum concentration-time curve from time zero to time of last measurable concentration. |
4 Weeks
|
|
Apparent terminal half-life (t1/2) of AZD0486
大体时间：From screening until 90 Days after end of treatment
|
Terminal half-life (t1/2,) will be determined after infusion in Cycle 1 using non-compartmental methods. |
From screening until 90 Days after end of treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Anti-Lymphoma Activity by Objective Response Rate (ORR)
大体时间：48 months
|
Objective response rate is defined as the proportion of subjects with a confirmed partial or complete response to treatment |
48 months
|
|
Anti-Lymphoma Activity by Progression-Free Survival (PFS)
大体时间：48 months
|
Progression-free survival time is defined as the time from the first dose of AZD0486 to progression or death, whichever occurs first |
48 months
|
|
Anti-Lymphoma Activity by Duration of Objective Response (DOR)
大体时间：48 months
|
The duration of objective response for a subject is defined as the time from the initial objective response to disease progression or death, whichever occurs first |
48 months
|
|
Anti-Lymphoma Activity by Clinical Benefit Rate
大体时间：48 months
|
Clinical benefit rate is defined as the proportion of subjects with a confirmed complete response, partial response or minor response, or stable disease for at least 24 weeks after responding to treatment |
48 months
|
合作者和调查者
赞助
调查人员
- 研究主任：David Sermer, MD、AstraZeneca
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- D7400C00006
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria:
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.